Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)

• Status: Completed
• Trial end date: 2008-06-11

Summary

A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin/peroxisome proliferator-activated receptor gamma (PPARg) agonist combination therapy.

• Phase: Phase 3

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Glipizide; Metformin; Rosiglitazone; Sitagliptin Phosphate